BNP Paribas Financial Markets
PHAT icon

BNP Paribas Financial Markets’s Phathom Pharmaceuticals PHAT Stock Holding History

BNP Paribas Financial Markets’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.3K Sell
8,692
-2,640
-23% -$30.1K ﹤0.01% 4586
2026
Q1 		$126K Buy
11,332
+1,542
+16% +$19.5K ﹤0.01% 4261
2025
Q4 		$162K Buy
9,790
+962
+11% +$13.7K ﹤0.01% 4154
2025
Q3 		$104K Buy
8,828
+3,756
+74% +$38.8K ﹤0.01% 4278
2025
Q2 		$48.6K Buy
5,072
+2,122
+72% +$11.7K ﹤0.01% 4265
2025
Q1 		$18.5K Sell
2,950
-36,582
-93% -$222K ﹤0.01% 4559
2024
Q4 		$321K Buy
+39,532
New +$490K ﹤0.01% 3585

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BNP Paribas Financial Markets's PHAT Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Phathom Pharmaceuticals (PHAT) stake by 23% in Q2 2026, selling an estimated $30.1K and leaving 8,692 shares worth $94.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4586.

BNP Paribas Financial Markets first reported a position in PHAT in Q4 2024 and has held it in 7 quarters since. The position peaked at $321K in Q4 2024. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • BNP Paribas Financial Markets held 8,692 shares of Phathom Pharmaceuticals worth $94.3K as of Q2 2026.
  • BNP Paribas Financial Markets sold 2,640 Phathom Pharmaceuticals shares in Q2 2026, an estimated $30.1K.
  • Phathom Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4586 holding.
  • BNP Paribas Financial Markets first reported a position in Phathom Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Phathom Pharmaceuticals position peaked at $321K in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.